In addition, early studies revealed a role for anti-CD47 mAbs in the priming of an adaptive immune response leading to enhanced anti-cancer activity by expanding tumor-specific cytotoxic T cells (23, 29, 30). This evidence concerns the gene CD47 and cancer.